FGF23

There are 93 papers on FGF23 in aging research: 4 trials and 34 observational studies in people, 21 in animals, 30 reviews.

Gene

93 papers study it32 findings

HGNCNCBI GeneTaxon

See all 93 papers on FGF23

At a glance

The findings reach people, from one lab or study. 12 independent labs in 9 countries; 4 trials, 3 with no results posted.

“In both cohorts, FGF23 associated negatively with high-density lipoprotein and apolipoprotein A1 (7% to 21% decrease per 1-SD increase in log FGF23; P<0.01)”
Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individualsArteriosclerosis, thrombosis, and vascular biology2010doi:10.1161/atvbaha.110.214619

None of its findings points the other way.

Cells, mice and humans: a single group. Worms or flies: nothing yet.
  • 12 independent labs in 9 countries
  • 4 trials, 3 with no results posted
  • Funders: National Institute of Diabetes and Digestive and Kidney Diseases and others
  • 4 of 4 trials sponsored by developers of drugs aimed at it
  • Human trial4
  • Humans34
  • Animals21
  • In silico1

Interventions

2

Glucagon-like peptide-2

downin mice1

1 study
  1. Glucagon-like peptide-2 decreases FGF23 in ovariectomized mice.

    “upregulated Runx2 expression, and downregulated FGF23 expression.”

    Animalsin ovariectomized micebone

    GLP-2 alleviates postmenopausal osteoporosis by acting on osteoblasts through the PI3K/AKT/FOXO1 signalling pathway to downregulate FGF23 expression

    Journal of orthopaedic surgery and research

More on Glucagon-like peptide-2

Coenzyme Q10 + selenium

downin humans1

1 study
  1. Coenzyme Q10 + selenium decreases FGF23 in humans (p = 0.01).

    “Following supplementation with selenium and coenzyme Q10, a significantly lower level of FGF-23 could be seen (p = 0.01).”

    Human trial48 monthsn = 219

    Decreased Concentration of Fibroblast Growth Factor 23 (FGF-23) as a Result of Supplementation with Selenium and Coenzyme Q₁₀ in an Elderly Swedish Population: A Sub-Analysis

    Cells

More on Coenzyme Q10 + selenium

Effects

13

Phosphate excretion

upin reviews2

2 studies
  1. FGF23 increases phosphate excretion (through the αKlotho-FGF23 signaling axis).

    “Through the αKlotho-FGF23 signaling axis, FGF23 regulates phosphate excretion by downregulating Na+-dependent phosphate transporter (NaPi-2a).”

    Reviewthrough the αKlotho-FGF23 signaling axis

    Regulation of αKlotho

    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

  2. FGF23 induces phosphate excretion.

    “a bone-derived hormone that induces phosphate excretion into urine”

    Review

    Klotho

    Pflugers Archiv : European journal of physiology

Coronary artery calcification

mediatesin silico1

1 study
  1. FGF23 mediates coronary artery calcification in PCSK9-CAC axis (mediated effect=0.024; mediation proportion=13.86%).

    “Mediation MR analysis suggested FGF23 as a partial mediator in the PCSK9-CAC axis (mediated effect=0.024; mediation proportion=13.86%).”

    In silicoin PCSK9-CAC axis

    Genetic association between PCSK9 and coronary artery calcification mediated by inflammatory cytokines

    Frontiers in cardiovascular medicine

More on Coronary artery calcification

Bone loss

no changein mice1

1 study
  1. FGF23 showed no clear effect on bone loss in mice.

    “Global knockout of Fgf23 in Fgf23/VDR compound mutants did not rescue the TAC-induced skeletal phenotype.”

    Animalsshown by global Fgf23 knockout in Fgf23/VDR compound mutants after transverse aortic constriction4 and 6 weeks

    Heart Failure but Not Myocardial Infarction Is Causing Bone Loss in Rodent Models in an FGF23-Independent Manner

    International journal of molecular sciences

Left ventricular hypertrophy

upin reviews1

1 study
  1. FGF23 induces left ventricular hypertrophy in CKD.

    “Moreover, FGF23 directly induces left ventricular hypertrophy (LVH) through FGF receptor-induced calcineurin/nuclear factor of activated T cells (NFAT) signaling in CKD.”

    Reviewin CKD

    Regulation of αKlotho

    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

More on Left ventricular hypertrophy

Handgrip strength

upin humans1

1 study
  1. FGF23 is linked with better handgrip strength in humans (maintenance hemodialysis) (beta = 5.39, 95% CI 2.07-8.72).

    “in multiple regression analyses, it was found to be a significant independent predictor of both handgrip strength (beta = 5.39, 95% CI 2.07-8.72)”

    Humansmaintenance hemodialysisserumn = 81

    Fibroblast Growth Factor 23 and Sarcopenia in Maintenance Haemodialysis Population

    Journal of cachexia, sarcopenia and muscle

Longevity

no changein humans1

1 study
  1. FGF23 was not clearly linked with longevity in humans.

    “but not with the other outcomes”

    Humans

    Genetically Predicted Fibroblast Growth Factor 23 and Major Cardiovascular Diseases, Their Risk Factors, Kidney Function, and Longevity: A Two-Sample Mendelian Randomization Study

    Frontiers in genetics

1,25(OH)2D

downin mice1

1 study
  1. FGF23 decreases 1,25(OH)2D in mice (elevated FGF23).

    “Elevated FGF23 suppressed 1,25(OH)2D and parathyroid hormone levels”

    Animalselevated FGF23

    FGF23 expression is stimulated in transgenic α-Klotho longevity mouse model

    JCI insight

More on 1,25(OH)2D

Phosphate reabsorption

downin reviews1

1 study
  1. FGF23 decreases phosphate reabsorption.

    “Fibroblast growth factor-23 (FGF23) is a bone-derived hormone known to suppress phosphate reabsorption and vitamin D hormone production in the kidney.”

    Reviewkidney

    Update on FGF23 and Klotho signaling

    Molecular and cellular endocrinology

CYP27B1

downin mice1

1 study
  1. FGF23 decreases CYP27B1 in Fgf-23(-/-) /hFGF-23-Tg double mutants vs Fgf-23(-/-) mice.

    “These changes were associated with reduced renal expression of NaPi2a and 1 alpha-hydroxylase, compared to Fgf-23(-/-) mice.”

    Animalsin Fgf-23(-/-) /hFGF-23-Tg double mutants vs Fgf-23(-/-) micekidney

    Amelioration of the premature ageing-like features of Fgf-23 knockout mice by genetically restoring the systemic actions of FGF-23

    The Journal of pathology

More on CYP27B1

SLC34A1

downin mice1

1 study
  1. FGF23 decreases SLC34A1 in Fgf-23(-/-) /hFGF-23-Tg double mutants vs Fgf-23(-/-) mice.

    “These changes were associated with reduced renal expression of NaPi2a and 1 alpha-hydroxylase, compared to Fgf-23(-/-) mice.”

    Animalsin Fgf-23(-/-) /hFGF-23-Tg double mutants vs Fgf-23(-/-) micekidney

    Amelioration of the premature ageing-like features of Fgf-23 knockout mice by genetically restoring the systemic actions of FGF-23

    The Journal of pathology

More on SLC34A1

All 13

Upstream

2

FOXO1

upin mouse cells1

1 study
  1. FOXO1 increases FGF23 in mouse cells.

    “Inhibition of FOXO1 can reduce FGF23 expression, whereas the overexpression of FOXO1 leads to an increase in FGF23 expression”

    Cellsosteoblasts

    GLP-2 alleviates postmenopausal osteoporosis by acting on osteoblasts through the PI3K/AKT/FOXO1 signalling pathway to downregulate FGF23 expression

    Journal of orthopaedic surgery and research

More on FOXO1

Cellular senescence

upin mouse cells1

1 study
  1. Cellular senescence increases FGF23 in mouse cells (senescence induced in MLO-Y4 cells).

    “senescence induction in MLO-Y4 cells increased the Fgf23 and Sost mRNA expression.”

    Cellssenescence induced in MLO-Y4 cells

    SIRT6-PAI-1 axis is a promising therapeutic target in aging-related bone metabolic disruption

    Scientific reports

More on Cellular senescence

Associations

14

Abdominal aortic calcification

upin silico1OR 1.082

1 study
  1. FGF23 raises the risk of abdominal aortic calcification in silico (OR 1.082, 95% CI 1.016-1.151).

    “Univariable MR analysis suggested a modest association between genetically predicted circulating FGF23 levels and a higher risk of AAC (odds ratio = 1.082, 95% confidence interval = 1.016-1.151, P = .013).”

    In silico

    FGF-23 is associated with increased risk of abdominal aortic calcification: A Mendelian randomization study with phosphate as a potential mediator

    Medicine

More on Abdominal aortic calcification

Capillary diameter

upin humans1

1 study
  1. FGF23 is associated with capillary diameter in humans (chronic kidney disease).

    “fibroblast growth factor 23 levels were positively related to capillary diameter”

    Humanschronic kidney diseasen = 96

    Evaluation of Endothelial Dysfunction in Geriatric Patients with Non-Dialysis Chronic Kidney Disease

    Journal of clinical medicine

eGFR slope

downin humans1

1 study
  1. FGF23 is associated with eGFR slope in humans (unadjusted/baseline correlation).

    “Higher baseline ePTFp and serum FGF23 were inversely correlated with eGFR slope.”

    Humansunadjusted/baseline correlation5 yearsn = 308

    Renal tubular calcium phosphate microcrystallopathy and age-related kidney function decline: The Aging Kidney Study

    Clinical kidney journal

More on eGFR slope

Sarcopenia

downin humans1OR 0.14

1 study
  1. FGF23 is linked with a lower risk of sarcopenia in humans (maintenance hemodialysis) (OR 0.14, 95% CI 0.02-0.75).

    “in multiple regression analyses, it was found to be a significant independent predictor of both handgrip strength (beta = 5.39, 95% CI 2.07-8.72) and sarcopenia (odds ratio = 0.14, 95% CI 0.02-0.75).”

    Humansmaintenance hemodialysisserumn = 81

    Fibroblast Growth Factor 23 and Sarcopenia in Maintenance Haemodialysis Population

    Journal of cachexia, sarcopenia and muscle

More on Sarcopenia

Frozen shoulder

upin humans1OR 1.2424

1 study
  1. FGF23 is linked with a higher risk of frozen shoulder in humans (OR 1.2424, P = 0.0316).

    “fibroblast growth factor-23 (FGF-23) impacted frozen shoulder (FS) (OR 1.2424, P = 0.0316)”

    Humans

    Causal relationship between molecular markers of biological aging and orthopedic diseases: A two-sample bidirectional Mendelian randomization study

    Experimental gerontology

More on Frozen shoulder

Arterial embolism and thrombosis

upin humans1OR 1.661

1 study
  1. FGF23 is linked with a higher risk of arterial embolism and thrombosis in humans (OR 1.661, 95% CI 1.051-2.624).

    “Causality was also identified between the genetically predicted levels of FGF23 and other arterial embolism and thrombosis (IVW: OR: 1.661, 95% CI 1.051-2.624, P = 0.029)”

    Humans

    Causal associations between epigenetic age and thromboembolism: a bi-directional two-sample Mendelian randomization study

    Clinical epigenetics

More on Arterial embolism and thrombosis

Calcific aortic valve stenosis

upin silico1

1 study
  1. FGF23 raises the risk of calcific aortic valve stenosis in silico.

    “genetic mimicry of serum FGF23 elevation was associated with increased CAVS risk”

    In silico

    Genetic association of serum calcium, phosphate, vitamin D, parathyroid hormone, and FGF23 with the risk of aortic stenosis

    NPJ cardiovascular health

More on Calcific aortic valve stenosis

Type 2 diabetes

downin humans1OR 0.7

1 study
  1. FGF23 is linked with a lower risk of type 2 diabetes in humans (OR 0.70 (95% CI: 0.52-0.96)).

    “type 2 diabetes mellitus (T2DM) (OR: 0.70, 95% CI: 0.52-0.96)”

    Humans

    Genetically Predicted Fibroblast Growth Factor 23 and Major Cardiovascular Diseases, Their Risk Factors, Kidney Function, and Longevity: A Two-Sample Mendelian Randomization Study

    Frontiers in genetics

More on Type 2 diabetes

Coronary artery disease

downin humans1OR 0.69

1 study
  1. FGF23 is linked with a lower risk of coronary artery disease in humans (OR 0.69 (95% CI: 0.52-0.91) per log-transformed pg/ml increase).

    “genetically predicted higher FGF23 was inversely associated with risk of CAD [odds ratio (OR): 0.69 per logtransformed FGF23 (pg/ml) increase, 95% confidence interval (CI): 0.52-0.91]”

    Humans

    Genetically Predicted Fibroblast Growth Factor 23 and Major Cardiovascular Diseases, Their Risk Factors, Kidney Function, and Longevity: A Two-Sample Mendelian Randomization Study

    Frontiers in genetics

More on Coronary artery disease

Cardiovascular function

mixedin reviews1

1 study
  1. FGF23 is associated with cardiovascular function.

    “FGF23 has emerged as a pleiotropic endocrine and auto-/paracrine factor influencing not only mineral metabolism but also cardiovascular function.”

    Reviewcardiovascular system

    Update on FGF23 and Klotho signaling

    Molecular and cellular endocrinology

All 14

Funding

4 grants since 2018

National Institute of Diabetes and Digestive and Kidney Diseases$3MJapan Society for the Promotion of Science¥17.3MNational Institute on Aging$3.1M

Latest

Dec 2025: 2Jan 2026: 3Feb 2026: 3Mar 2026: 2Apr 2026: 1May 2026: 1Jun 2026: 1Jul 2026: 0Aug 2026: 1Sep 2026: 1Oct 2026: 1Nov 2026: 016 papers in 12 months

See all 93 papers on FGF23